12:00 AM
Oct 13, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Durezol: Phase IIIb data

In a double-blind Phase IIIb trial in 124 patients undergoing unilateral ocular surgery, Durezol given 4 times daily met the primary endpoint of percentage of patients with a clinical response on day 14 compared with placebo (81% vs. 25%, p<0.0001). Also, significantly more...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >